Business
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy
About this update from Angiodynamics, Inc.
[{"type":"text","content":" LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025.\n\nFiscal Year 2025 Third Quarter Highlights\n\n\n\n \n\n\n\nQuarter Ended\nFebruary 28, 2025\n\n\n\nPro Forma* YoY Growth\n\n\n\n\n\nPro Forma* Net Sales\n\n\n\n$72.0 million\n\n\n\n9.2%\n\n\n\n\n\nMed Tech Net Sales\n\n\n\n$31.3 million\n\n\n\n22.2%\n\n\n\n\n\nMed Device Net Sales\n\n\n\n$40.7 million\n\n\n\n0.9%\n\n\n\n\n\nGAAP gross margin of 54.0%\n\n\nGAAP loss per share of $(0.11)\n\n\nAdjusted loss per share of $(0.08)\n\n\nAdjusted EBITDA of $1.3 million\n\n\nInitiated the AMBITION BTK RCT and Registry to generate definitive clinical evidence supporting the use of the Auryon Atherectomy System in treating below the knee lesions in patients with critical limb ischemia\n\n\nPublished APEX-AV trial results in JSCAI demonstrating the safety and efficacy of the AlphaVac F1885 System\n\n\nReceived FDA 510(k) clearance for NanoKnife System for prostate tissue ablation\n\n\nIncreasing fiscal year 2025 guidance for net sales, Med Tech net sales growth, gross margin, Adjusted EBITDA, and Adjusted EPS\n\n\n\n\n*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued Radiofrequency and Syntrax products in February 2024.\n\n\n\n\n\"We are very pleased with our third quarter performance as we continued to drive strong topline growth and adjusted EBITDA profitability. Our ability to deliver consistently strong results comes as a result of the significant transformation we have undergone over the last few years to simplify our business and focus on large, fast-growing MedTech markets,\" said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. \"To that end, we're seeing impressive momentum across our MedTech franchise, which grew over 20% for the second quarter in a row, driven by growth within each of our MedTech platform technologies, Auryon, AngioVac, AlphaVac, and NanoKnife. In lock-step with this growth, we co...